PCH
NBIX icon

Polar Capital Holdings’s Neurocrine Biosciences NBIX Stock Holding History

Polar Capital Holdings’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,000
Closed -$2.73M – 306
2024
Q4 		$2.73M Hold
20,000
– – 0.02% 264
2024
Q3 		$2.3M Sell
20,000
-590,552
-97% -$81M 0.01% 265
2024
Q2 		$84.1M Sell
610,552
-165,004
-21% -$22.6M 0.5% 57
2024
Q1 		$107M Sell
775,556
-60,277
-7% -$8.23M 0.56% 45
2023
Q4 		$110M Buy
835,833
+510,833
+157% +$58.8M 0.67% 36
2023
Q3 		$36.6M Sell
325,000
-50,000
-13% -$5.27M 0.27% 95
2023
Q2 		$35.4M Buy
+375,000
New +$36.6M 0.18% 112
2023
Q1 		– Sell
-173,946
Closed -$20.8M – 315
2022
Q4 		$20.8M Hold
173,946
– – 0.17% 142
2022
Q3 		$18.5K Sell
173,946
-610,341
-78% -$61.9M 0.12% 149
2022
Q2 		$76.5K Buy
784,287
+25,000
+3% +$2.31M 0.45% 55
2022
Q1 		$71.2K Buy
759,287
+725,000
+2,115% +$61.4M 0.32% 72
2021
Q4 		$2.92K Buy
34,287
+4,472
+15% +$411K 0.01% 283
2021
Q3 		$2.86K Sell
29,815
-134,158
-82% -$12.7M 0.01% 295
2021
Q2 		$16K Buy
163,973
+35,156
+27% +$3.37M 0.07% 192
2021
Q1 		$12.5M Buy
128,817
+6,000
+5% +$629K 0.08% 192
2020
Q4 		$11.8M Buy
+122,817
New +$11.9M 0.07% 198

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Polar Capital Holdings's NBIX Position: Q1 2025 in Review

Polar Capital Holdings sold out of Neurocrine Biosciences (NBIX) in Q1 2025, closing a stake of 20,000 shares — an estimated $2.73M sold.

Polar Capital Holdings first reported a position in NBIX in Q4 2020 and held it in 16 quarters. The position peaked at $110M in Q4 2023. 586 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

  • Polar Capital Holdings reported no remaining Neurocrine Biosciences position as of Q1 2025 after selling out during the quarter.
  • Polar Capital Holdings sold 20,000 Neurocrine Biosciences shares in Q1 2025, an estimated $2.73M.
  • Polar Capital Holdings first reported a position in Neurocrine Biosciences in Q4 2020 and held it in 16 quarters.
  • Polar Capital Holdings's Neurocrine Biosciences position peaked at $110M in Q4 2023.
  • 586 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on Polar Capital Holdings's 13F filing for Q1 2025, filed 15 May 2025.